---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-015650"
form_type: "8-K"
ticker: "SSKN"
cik: "0001051514"
company_name: "STRATA Skin Sciences, Inc."
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T06:55:59.832674+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Strata Skin Sciences Q4 rev $8.7M, net loss $3.8M; FY rev $33.4M, net loss $10.8M

## Summary
- Q4 2023 revenue $8.7M vs $10.6M in Q4 2022; net loss $3.8M ($0.11 EPS) vs $0.2M loss.
- Full-year 2023 revenue $33.4M vs $36.2M; net loss $10.8M ($0.31 EPS) vs $5.6M loss.
- Recorded $2.3M goodwill impairment in dermatology recurring procedures segment.
- Installed XTRAC base 923 devices; launched TheraClear X acne system with 92 devices in operation.
- Dr. Dolev Rafaeli appointed Vice-Chairman, President and CEO in October 2023.

## SEC filing metadata
- accession: 0001140361-24-015650
- form_type: 8-K
- ticker: SSKN
- cik: 0001051514
- company_name: STRATA Skin Sciences, Inc.
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1051514/000114036124015650/0001140361-24-015650-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1051514/000114036124015650/ef20025035_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-015650
- JSON: https://secwatch.observer/filing/0001140361-24-015650.json
- Plain text: https://secwatch.observer/filing/0001140361-24-015650.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.